Ipsen, Invida Group Sign Agreement To Commercialize Drugs In South-East Asia

SHANGHAI- The French firm Ipsen and Singapore's Invida have forged an exclusive distribution and promotion deal covering a number of Ipsen's oncology and endocrinology drugs in select South-East Asian countries. The agreement is expected to help expand the geographical reach of Ipsen's specialty-care portfolio in the Asia Pacific region

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip